Skip to content

Adaptive Planning in Bladder Cancer

Adaptive - Predictive Planning for Hypofractionated Bladder Radiotherapy

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01000129
Acronym
APPLY
Enrollment
32
Registered
2009-10-22
Start date
2009-01-31
Completion date
2010-12-31
Last updated
2009-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Radiotherapy, Bladder cancer, Adaptive planning

Brief summary

To demonstrate that radiotherapy treatments for bladder cancer can be delivered with greater accuracy using a new planning method and that this method can be used simply and effectively by those delivering treatment.

Detailed description

This study integrates a novel adaptive planning methodology, Adaptive-Planning Organ LOcalisation (A-POLO), with optimised margins and cone beam CT technology for improving the accuracy of radiotherapy treatment delivery. The previous study (CCR2873, REC 07/Q0801/13) evaluated the use of cone beam CT in radiotherapy for bladder cancer. A larger than expected number of bladder radiotherapy treatments were seen to have been delivered with some element of geographic miss. Using the novel adaptive planning method these fractions of radiotherapy could have been correctly treated. The feasibility of this method has been proven in the previous study, particularly it has been shown that this method is appropriate and provides a simple solution to the problem. It can be carried out by the radiographers at the treatment unit without adding extra time to the treatment.

Interventions

OTHERCone beam CT acquisition

Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.

OTHERAdaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)

Planning CT scan performed by qualified planning radiographers

Sponsors

Institute of Cancer Research, United Kingdom
CollaboratorOTHER
Royal Marsden NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 * Histologically confirmed invasive carcinoma of the bladder * Patient planned to receive hypofractionated radiotherapy to the bladder. * No previous pelvic radiotherapy * Written informed consent given according to ICH/GCP and national/local regulations.

Exclusion criteria

* Urinary catheter in situ: the presence of a urinary catheter degrades cone beam image quality and thus images would not be evaluable. Patients with a urinary catheter would not be expected to show variation in bladder filling.

Design outcomes

Primary

MeasureTime frame
Assessment performed online at the treatment unit & verified offline by additional observer. Primary endpoint is met if there is greater than 75% concordance between the assessment made online & offline.

Countries

United Kingdom

Contacts

Primary ContactDr Robert Huddart
robert.huddart@icr.ac.uk02086613457
Backup ContactBernadette Johnson
bernadette.johnson@rmh.nhs.uk02086613434

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026